Navigation Links
Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online
Date:9/8/2010

IRVINE, Calif., Sept. 8 /PRNewswire/ -- Cardiogenesis Corporation (OTCQB: CGCP) today announced that the Wall Street Reporter has interviewed Cardiogenesis' Executive Chairman Paul J. McCormick.  The interview includes a discussion of the Company's results for the first half of 2010, including an approximate 17% year-over-year increase in disposable handpiece sales for the first half of 2010 and an overview of the company and its core technologies.  The interview also covers Cardiogenesis' progress towards initiating a pivotal trial for its PHOENIX™ System in patients with refractory angina.  The PHOENIX handpiece is the first device specifically designed to allow physician-directed tissue stimulation and injections of biologic or pharmacologic agents to pre-determined areas of myocardium.

The interview is available at www.wallstreetreporter.com, or directly via this link: http://www.wallstreetreporter.com/2010/09/cardiogenesis-corporation-otc-qb-cgcp-management-interview/.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the therapies for the treatment of chronic cardiac ischemia. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease.  For more information on the company and its products, please visit the Cardiogenesis website at http://www.cardiogenesis.com.

Safe Harbor Statement

This press release and Mr. McCormick's interview contain forward-looking statements, including, without limitation, with respect to the Company's expectation to begin a U.S. clinical trial of the Company's PHOENIX Combination Delivery System.  Any forward-looking statements in this news release are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; the effects of recent disruptions in global credit and equity markets and other adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2009 and the Company's other filings with the Securities and Exchange Commission. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


'/>"/>
SOURCE Cardiogenesis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
2. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
3. Cardiogenesis Reports Third Quarter 2009 Results
4. Cardiogenesis Corporation to Present at Noble Financial - ONTRACK 2010
5. Cardiogenesis (CGCP) Listing Upgraded to New OTCQB(TM) Market for All U.S. Registered and Reporting OTC Securities
6. Cardiogenesis Corporation to Report 2010 Second Quarter Results on August 4th
7. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
9. Industry Executives Finding Value in Shift of Scientific Publications
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
11. Evalve Expands Executive Leadership Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... FLINT, Mich. , May 8, 2017  Diplomat ... WRB Communications, Inc. ("WRB"), a health care ... . WRB specializes in relationship management ... organizations. WRB will ... of Diplomat,s commercialization support services for manufacturers, biotech firms, ...
(Date:5/4/2017)...  Fortuna Fix Inc. (" Fortuna "), a private, ... eliminate the need for embryonic and fetal stem cells by ... Fortuna announced today the launch of ... , MD, PhD; Father Kevin FitzGerald , S.J., PhD; ... James Giordano , PhD. "We are excited ...
(Date:5/4/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health ... announced that it is teaming up with Auto Control ... lower diabetes healthcare costs in Canada ... available throughout all provinces and territories in ... additional savings when shopping for Dario supplies in local ...
Breaking Medicine Technology:
(Date:5/19/2017)... ... May 19, 2017 , ... In a continuous effort to ... a luxury online mattress company that specializes in natural and organic latex mattresses, has ... autism organization) for every unique share their recent viral Facebook video receives, ...
(Date:5/19/2017)... , ... May 19, 2017 , ... When Kyle Busch ... his name will already appear on two major research studies that could impact the ... with Dr. Matt Daggett, KCU alumnus and an orthopedic surgeon, alongside an international team ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Miller Agency, a Jacksonville ... and business owners in the region, is embarking on a cooperative charity event ... families. , Multiple sclerosis (MS) is a demyelinating disease that affects the insulation ...
(Date:5/19/2017)... ... ... As a groundbreaking surgeon on the frontline of prostate cancer treatment, Dr. ... the disease, he says, can make a world of difference. , ... Georgia Comprehensive Cancer Control’s (GC3) Prostate Cancer Task Force and its suggestion to recommend ...
(Date:5/19/2017)... ... May 18, 2017 , ... Eisenhower Fellowships ... eight American presidents of both political parties, will become the 9th Chairman of ... L. Powell, USA (Retired) as Chairman in May, 2018. , Secretary Gates served ...
Breaking Medicine News(10 mins):